A Phase II Study of Fruquintinib Combined With Capecitabine as First-line Treatment for Advanced Metastatic Colorectal Cancer Unsuitable for Intravenous Chemotherapy
Ontology highlight
ABSTRACT: This is a single center, open-labeled, single arm phase II study aimed to investigate the efficacy and safety of fruquintinib combined with capecitabine as first-line treatment for advanced metastatic colorectal cancer patients unsuitable for intravenous chemotherapy.
DISEASE(S): Unresectable Metastatic Colorectal Cancer,Colorectal Neoplasms
PROVIDER: 2375937 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA